The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2019 | The use of imaging to determine MRD
Elena Zamagni, MD, PhD from the University of Bologna, Bologna, Italy discusses the use of imaging techniques to determine measurable residual disease outside of the bone marrow in patients with multiple myeloma. PET-CT and functional MRI are two techniques currently in use and are being further investigated in clinical trials, as described by Dr Zamagni. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.
